-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 3, 2021, GRO Biosciences announced the completion of a US$25 million Series A financing
The company's proprietary GRO platform is based on research in the laboratory of Professor George Church of Harvard Medical School, a pioneer in gene sequencing and gene editing
In addition, GRObio is advancing products containing unnatural amino acids in two directions
ProGly technology consists of unnatural amino acids carrying glycans, which can induce or suppress immune responses
Reference materials:
[1] GRO Biosciences Announces $25M Series A Financing Led by Leaps by Bayer and Redmile Group.
(The original text has been deleted)